ArticleBiotechnology journal2013
Transcriptional regulation improves the throughput of three-hybrid counter selections in Saccharomyces cerevisiae.
Article in Biotechnology journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The yeast three-hybrid (Y3H) assay expands the fields of drug discovery and protein engineering by enabling the search of large variant libraries for targets that do not inherently produce a distinct, measurable phenotype. The Y3H assay links the DNA-binding and activation domains of a transcription factor via a chemically synthesized heterodimeric small molecule, thereby activating a downstream reporter gene. Although the Y3H assay has been successfully applied as a positive selection to discover novel drug targets and to evolve proteins with improved functions, its expansion into applications requiring a high-throughput, versatile selection against transcriptional activation has been hindered by its limited dynamic range as a counter selection. Here, we describe the development of a second-generation Y3H counter selection that uses the dual tetracycline (Tet) system to tighten transcriptional regulation of the reporter gene. The Tet Y3H counter selection has an improved dynamic range and provides enrichment from mock libraries of up to 10⁶, a 10⁴-fold improvement over our original Y3H counter selection. This enhanced dynamic range brings the Y3H counter selection to a standard that is suitable for real-world protein engineering applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.